Steve Mandel's Lone Pine Capital disclosed a $4.2 billion reduction in technology holdings during Q4 2024, marking the fund's sharpest sector rotation in three years. The Greenwich-based manager cut its equity AUM from $27.0 billion to $22.8 billion while shifting capital into healthcare equipment and industrial manufacturers. The 13F filing showed complete exits from five software names that had been core positions since 2022.
The fund eliminated its $1.8 billion stake in Microsoft and reduced Alphabet exposure by 63%, bringing the position down to $420 million. Amazon holdings fell 41% to $890 million. Lone Pine simultaneously built a $1.1 billion position in Intuitive Surgical and added $680 million in Thermo Fisher Scientific. The portfolio's tech weighting dropped from 47% to 29%, while healthcare climbed from 18% to 31%.
The move reflects growing allocator concern over software multiples in a sustained higher-rate environment. Lone Pine had entered 2024 with a concentrated bet on cloud infrastructure and AI tooling, but the fund's Q3 letter—circulated to LPs in October—flagged valuation compression risk if the Fed held rates above 4.5% through mid-2025. The Microsoft exit occurred entirely in November, according to transaction timestamps, weeks before the stock pulled back 9% on Azure growth deceleration.
Lone Pine's industrial exposure doubled to $3.4 billion, led by new stakes in RTX Corporation ($740 million) and General Electric ($590 million). The fund also initiated a $480 million position in Honeywell, targeting companies with defense and aerospace tailwinds from the Pentagon's shift toward multi-domain operations. These additions align with allocator flows into late-cycle value plays—industrials absorbed $8.2 billion in institutional capital during Q4, per EPFR data.
The healthcare tilt carries execution risk. Intuitive Surgical trades at 62x forward earnings, near the top of its five-year range, and faces reimbursement headwinds as CMS finalizes 2026 hospital payment rates. Lone Pine's entry price averaged $487 per share, leaving little margin for procedure-volume disappointment. The fund's medical device basket now accounts for 14% of AUM, up from 3% in Q3.
Allocators should monitor Lone Pine's Q1 2025 filing in mid-May for follow-through. If the fund continues trimming software, particularly SaaS names with subscription concentration risk, it signals conviction in a multi-quarter rotation. Watch also for additions to the pharma sub-sector—Lone Pine held no large-cap biopharma as of December 31, an unusual underweight given the group's 17% rally since October. The next LP letter, typically circulated in early April, may detail the fund's view on tech re-entry points.
Lone Pine returned 11.2% net in 2024, trailing the S&P 500 by 360 basis points. The portfolio now holds 68 positions, down from 89 in Q3, with top-ten concentration at 51%.